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Methods: UA patients who treated with statin (n¼6) and without statin (n¼6) whole
blood sample were detected miRNAs proﬁle by using MiRNAs taqman low density
array. 17 signiﬁcant differential upregulated miRNAs were signiﬁcant. MiRNAs tar-
gets were predicted by three bioinformatic tools. Putitive targets were clustered into
different pathway and cell types by DAVID functional tool. GEO database Stable
(n¼6) vs rupture plaque macrophage (n¼5); Early (n¼13) vs Advance carotid
atherosclerotic plaque (n¼16) provided information were calculated by sam to ﬁgure
out pathway in the rupture plaque. By using cytoscape to visualize the miRNAs
regulated functional network.
Results: From the miRNA array data, 17 differential expressed miRNAs in the statin
group compare without statin group in the UA patients.
MiRNAs cells type target pathway network appears that its targets in a. plaque
macrophage enriched in pathway of hemostasis, signaling in NGF, opioid signaling;
b. Platelet in pathway of hemostasis, signaling by Rho GTPases, signaling by NGF,
integrin cell surface interactions, signaling by insulin receptor, signaling by EGFR;
c. Monocyte in pathway of Signaling by NGF, Apoptosis, hemostasis, signaling by
PDGF, Axon guidance, signaling by Notch; d. Endothelial cell. Signaling by NGF,
Apoptosis signaling by Rho GTPases, membrane trafﬁcking etc. MiRNAs targeted
resident macrophage of rupture plaque are major in signaling for NGF, signaling by
Rho GTPases and hemostasis. The NGF signaling pathway, hemostasis and Rho
GTPase signaling also emerged in the carotid plaque. After combine the two miRNA
target networks, only the hemostasis, Rho GTPase singling pathway and signaling in
immune system had been targeted.
Conclusions: Our bioinformatic analysis on UA patients’ miRNAs proﬁles suggested
MiRNAs functioning in the plaque macrophage and platelet miRNA targets are major
enrich in hemostasis, while in monocyte NGF apoptosis and Rho GTPase and in
endothelial cell. Further integrate data miRNAs and mRNA in atherosclerotic lesion
indicate that statin induced miRNAs target signaling pathway of Rho GTPase,
Hemostasis in plaque and additional signaling in immune system was targeted by
miRNAs in vulnerable plaque.
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Objectives: It has been previously demonstrated that hypoxia preconditioning (HP)
potentiated the therapeutic effect of mesenchymal progenitor cells (MPC) on
myocardial infarction. Given that exosomes, released from various cells, have been
well recognized to play critical roles in cell-to-cell communication, we documented
the exosomal miRNAs secreted from MPC with HP and examined their roles in
cardiac function preservation after myocardial injury.
Methods: For HP, MPC was subjected to repeated cycles of hypoxia (30 min) with
intermittent reoxygenation (10 min) for three cycles. In vitro, CM was incubated in
hypoxia for 24 hours to establish injury model. Concentrated conditioned medium
(CdM) of MPC was extracted to be applied in the subsequent experiments, and
exosome was isolated from CdM by differential centrifugation. GW4869, a special
inhibitor to exosome, was used to interdict exosome release. The miRNAs tran-
scriptome in exsome was analyzed by microarray and veriﬁed by quantiﬁed-PCR.
Alternatively, ago-miR-210 or antago-miR-210 transfection was performed to up- or
down-regulate intracellular miR-210 in MPC, respectively. In vivo, rats were sub-
jected to left anterior descending (LAD) ligation followed by injection of either CdM-
MPCcontrol, CdM-MPCHP, CdM-MPCHP-GW4869, or exo-MPCHP into the peri-infarct
region, which were followed up for 4 weeks.
Results: It was demonstrated that CdM-MPCHP exerted potent beneﬁcial effect on the
survival of CM in hypoxia, as indicated in a remarkable decrease in apoptosis rate of
CM treated with CdM-MPCHP compared to that of with CdM-MPCcontrol
[(12.32.61) % vs. (28.73.73) %, P<0.05] in TUNEL assay; however, there was an
obvious raise in CM apoptosis between CdM-MPCHP-GW4869 group and CdM-
MPCHP one (P<0.05). Among 26 signiﬁcantly up- or down-regulated miRNAs in
exosome derived from CdM-MPCHP compared to that from CdM-MPCcontrol, miR-
210, a survival-associated miRNA, was further investigated. It was suggested that
miR-210 in CdM-MPCHP was signiﬁcantly decreased following CM cultured in this
medium (P<0.05); meanwhile, the expression of miR-210 in CM cultured with CdM-
MPCHP was statistically increased by 2.76 fold compared to the control. After over-
expression of miR-210 in MPC, exosome was isolated from CdM-MPCmiR-210, and
added into CM medium. The co-location detection with an immunoﬂuorescence in
miR-210 and two special markers of exosome, CD81 and CD63, was performed to
verify that miR-210 was secreted through exosome release. Afterwards, it was
observed that miR-210 was internalized by CM via exosome-intake, resulting in a
prominent rise in CM survival in a similar manner to CdM-MPCHP incubation.
Intriguingly, miR-210 knock-down in MPC remarkably abolished the cardioprotection
of both CdM-MPCHP and exo-MPCHP. In vivo, a dramatically favorable effect, either
of CdM-MPCHP or of exo-MPCHP, was discovered on cardiac remodeling after
myocardial infarction compared with that of CdM-MPCcontrol, with a remarkable
enhancement of left ventricular ejection function (LVEF) by 1.31 fold or by 1.27 fold
respectively; however, there was not statistical difference in LVEF could be indicated
between CdM-MPCHP-GW4869 group and CdM-MPCcontrol one.
Conclusions: Our investigation evidenced that exosome-mediated transfer of miR-
210 from MPC to CM facilitated the myocardial survival in hypoxia, providing a
novel insight into the mechanism of cell-based treatment for cardiovascular diseases.JACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/BGW25-e5168
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Objectives: Atrial ﬁbrillation (AF) is the most common sustained arrhythmia yet
current pharmacological treatments are only moderately effective. Enhanced sarco-
plasmic reticulum (SR) Ca2+ leak via ryanodine receptor type-2 (RyR2) contributes to
AF pathogenesis and preliminary data in atrial samples from paroxysmal AF (pAF)
patients showed an upregulation of RyR2 proteins with no change in mRNA levels.
This suggests that post-transcriptional regulation of RYR2 by microRNAs (miRNAs)
may play a role in RyR2 dysregulation in pAF. Since bioinformatic analysis suggests
that miR-106b and miR-93, members of the miR-106b-25 cluster, could target RYR2-
3’UTR, we hypothesized that loss of the miR-106b-25 cluster may promote AF via
enhanced RyR2-mediated SR Ca2+ leak.
Methods: RYR2-3’UTR luciferase reporter assay was performed in HEK293 cells.
Telemetry ECG recordings, intracardiac electrophysiology (EP) studies, Ca2+ imaging
and immunocytochemistry (ICC) using isolated atrial myocytes, and Western blotting
(WB) were performed in miR-106b-25 homozygous knockout (miR-106b-25 -/-) mice
and wildtype (WT) littermates. Levels of mRNAs and mature miRNAs were measured
using quantitative real-time (qRT) -PCR in both mice and atrial samples from pAF
patients.
Results: Luciferase reporter assay conﬁrmed that miR-93 targets RYR2-3’UTR. WB
and qRT-PCR revealed an upregulation of RyR2 proteins in miR-106b-25 -/- atria
(n¼7) by 42% (P<0.01 vs. WT, n¼4) but unchanged mRNA levels. ICC showed that
the subcellular localization of RyR2 remained unchanged in miR-106b-25 -/- atrial
myocytes. Ca2+ spark frequency (CaSF) normalized to SR load and total SR Ca2+ leak
were doubled in miR-106b-25 -/- atrial cells (both P<0.05 vs. WT; 3 animals/group).
These increases in CaSF and SR Ca2+ leak were normalized to WT levels when miR-
106b-25 -/- atrial myocytes were incubated with the RyR2-blocker K201 (1 mmol/L;
both P<0.05 vs. untreated cells). Telemetry and EP studies showed that miR-106b-25
-/- mice exhibited more atrial ectopy (82 events/hr, n¼8) than WT mice (1.00.5
events/hr, n¼6, P<0.05) and were more susceptible to pacing-induced AF (75%,
n¼8) than WT mice (12.5%, n¼8, P<0.05). RyR2-blocker K201 (10mg/kg, i.p.)
reduced the incidence of pacing-induced AF in miR-106b-25 -/- mice (14.3%, n¼7,
P<0.05 vs miR-106b-25 -/-). Finally, qRT-PCR demonstrated that the miR-106b-25
cluster is downregulated in atrial samples from pAF patients compared with patients in
sinus rhythm (n¼5/group, P<0.05).
Conclusions: These results suggest that abnormal miR-106b-25 regulation of RYR2
expression is an important molecular mechanism involved in the proarrhythmic RyR2
dysregulation in pAF patients. miR-93 mimic may constitute a novel therapeutic
strategy for pAF patients associated with RyR2 hyperactivity
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Objectives: Atrial ﬁbrillation (AF) is the most common form of sustained cardiac
arrhythmia in humans and is responsible for substantial morbidity and mortality
worldwide. Emerging evidence indicates that abnormal cardiovascular development is
involved in the pathogenesis of AF.
Methods: In this study, the coding exons and splice sites of the NKX2-5 gene, which
encodes a homeodomain-containing transcription factor essential for cardiovascular
genesis, were sequenced in 146 unrelated patients with lone AF as well as the
available relatives of the mutation carriers. A total of 700 unrelated ethnically matched
healthy individuals used as controls were genotyped. The disease-causing potential of
the identiﬁed NKX2-5 variations was predicted by Mutation Taster and PolyPhen-2.
The functional characteristics of the mutant NKX2-5 proteins were analyzed using a
dual-luciferase reporter assay system.
Results: As a result, two heterozygous NKX2-5 mutations, including a previously re-
ported P.E21Q and a novel P.T180A mutation, were identiﬁed in two families with AF
transmitted in an autosomal dominant pattern. The mutations co-segregated with AF in
the families with complete penetrance. The detected substitutions, which altered the
amino acids highly conserved evolutionarily across species, were absent in 700 control
individuals and were both predicted to be causative. Functional analyses demonstratedasic and Translational Medicine C59
that the NKX2-5 mutants were associated with signiﬁcantly decreased transcriptional
activity compared with their wild-type counterpart.
Conclusions: The ﬁndings expand the spectrum of NKX2-5 mutations linked to AF
and provide additional evidence that dysfunctional NKX2-5 may confer vulnerability
to AF, suggesting the potential beneﬁt for the early prophylaxis and personalized
treatment of AF.
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Objectives: This study is designated to examine if and how ox-LDL triggers heart
failure.
Methods:We investigated the role of ox-LDL and LOX-1 in heart failure. Bax, Bcl-2
were detected by Real-time RT-PCR. In addition, LOX-1 was detected by western blot
analysis.
Results: Infusion of ox-LDL in mice for 4 weeks resulted in marked heart failure, as
characterized by an increase in heart size, heart /body weight ratio, and plasma BNP
levels, in conjunction with a lowered LV constriction function. Moreover, ox-LDL
treatment promoted apoptosis and upregulation of LOX-1 protein in both cultured
cardiomyocytes and murine hearts. Real-time RT-PCR ﬁndings revealed that ox-LDL
treatment increased Bax/Bcl-2 ratio in cardiomyocytes. Moreover, inhibition of LOX-
1 attenuated not only ox-LDL-induced cardiomyocyte apoptosis but also heart failure.
Conclusions: Our results indicate that ox-LDL triggers cardiomyocyte apoptosis and
heart failure possibly through LOX-1 and apoptosis.
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Renal sympathetic denervation prevents left ventricular remodeling and
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Objectives: This study investigated the effect of catheter-based renal sympathetic
denervation (RDN) on left ventricular remodeling and cardiac function in a porcine
model of heart failure induced by myocardial infarction.
Methods: Myocardial infarction was created by a percutaneous, permanent left
anterior descending artery occlusion in Chinese Guizhou miniature swine (n¼20).
After myocardial infarction, 12 pigs underwent bilateral RDN and 8 pigs served
as controls. Haemodynamic and echocardiographic data were measured at baseline
and 8 weeks after myocardial infarction. Infarct size, histological changes and
collagen volume fraction were evaluated after 8 weeks. Plasma norepinephrine, renin
activity, angiotensin II and cardiac angiotensin II were also determined by
radioimmunoassay.
Results: Compared with controls, RDN-treated pigs exhibited signiﬁcantly greater LV
ejection fraction (50.63.0% vs. 41.42.8%, P<0.01), systolic thickening fraction in
the infarcted LV wall, and maximum LV dP/dt, as well as lower LV end-diastolic
pressure. In addition, RDN reduced infarct size (7.70.9% vs. 12.92.1%, P<0.01)
and prevented cardiac hypertrophy and ﬁbrosis. What’s more, Plasma norepinephrine
concentration, renin activity, angiotensin II concentration and cardiac angiotensin II
level were decreased in RDN-treated pigs (P<0.05).
Conclusions: In this preclinical model of heart failure, renal sympathetic denervation
prevents left ventricular remodeling and improves cardiac function.
GW25-e1565
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Objectives: Structural and functional disruption of microvascular barrier caused by
ischemia/reperfusion results in uncontrolled inﬂammation and ischemia/reperfusion
injury (IRI). Hyperglycemia may aggravate myocardial IRI since it worsens the barrier
function. Whether Tongxinluo (TXL) is involved in reperfued diabetic heart protec-
tion through protecting cardiac microvascular endothelial cells (CMECs) is unknown.
In order to conﬁrm the effect and mechanism of TXL-mediated cardiac protection,
studies in vitro and in vivo were conducted.
Methods: HCMECs were cultured in normal (5.5mM) and high glucose (18mM)
for 48 h respectively followed by glucose-oxygen-serum deprivation (GOSD) for 2 h
and reoxygenation for 2 h. TXL (800mg/ml), PPAR-a inhibitor MK886 (1mM)
were supplemented. Endothelial monolayer permeability was assessed.VE-cadherin
internalization was detected by confocal microscope and western blotting.ICAM-1
expression was detected by western blotting.ZDF rats with Type 2 diabetes mellitus
(T2DM) underwent 45 min ligation and 3 h reperfusion of LAD. Vascular perme-
ability and infarct size were determined by FITC-dextran and TTC staining
seperately.C60 JACC Vol 64/16/Suppl C j OctobResults: Endothelial monolayer permeability was signiﬁcantly increased after the
GOSD/ reoxygenation treatment in a time and glucose concentration-dependent
manner. Compared with the control group, TXL dramatically decreased the ﬂuores-
cence intensity (1925138vs.3558133) and ICAM-1 expression, but remarkbly
increased the membrane/total VE-cadherin (35%4vs.84%6) in HCMECs. TXL
signiﬁcantly reduced ﬂuorescence intensity (2914388vs.4728483) and infarct size
(45%6vs.52%3) of ZDF rats with T2DM in AMI/reperfusion model compared
with control group. These protective effects of TXL were partly inhibited by MK886.
Conclusions: Accordingly, TXL protects reperfused diabetic heart through attenu-
ating VE-cadherin-mediated paracellular hyperpermeability via PPAR-a pathway.
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Objectives: Structural and functional disruption of microvascular barrier caused by
ischemia/reperfusion results in uncontrolled inﬂammation and ischemia/reperfusion
injury (IRI). Hyperglycemia may aggravate myocardial IRI since it worsens the barrier
function. Whether Tongxinluo (TXL) is involved in reperfused diabetic heart pro-
tection through protecting cardiac microvascular endothelial cells (CMECs) is un-
known. In order to conﬁrm the effect and mechanism of TXL-mediated cardiac
protection, studies in vitro and in vivo were conducted.
Methods: HCMECs were cultured in normal (5.5mM) and high glucose (18mM) for
48 h respectively followed by glucose-oxygen-serum deprivation (GOSD) for 2 h and
reoxygenation for 2 h. TXL (800mg/ml), PPAR-a inhibitor MK886 (1mM) were
supplemented. Endothelial monolayer permeability was assessed. VE-cadherin inter-
nalization was detected by confocal microscope and western blotting. ICAM-1
expression was detected by western blotting. ZDF rats with Type 2 diabetes mellitus
(T2DM) underwent 45 min ligation and 3 h reperfusion of LAD. Vascular perme-
ability and infarct size were determined by FITC-dextran and TTC staining
respectively.
Results: Endothelial monolayer permeability was signiﬁcantly increased after the
GOSD/ reoxygenation treatment in a time and glucose concentration-dependent
manner. Compared with the control group, TXL dramatically decreased the ﬂuores-
cence intensity (1925138 vs. 3558133) and ICAM-1 expression, but remarkably
increased the membrane/total VE-cadherin [ (354) % vs. (846) %] in HCMECs.
TXL signiﬁcantly reduced ﬂuorescence intensity (2914388 vs. 4728483) and
infarct size [ (456) % vs. (523) %] of ZDF rats with T2DM in AMI/reperfusion
model compared with control group. These protective effects of TXL were partly
inhibited by MK886.
Conclusions: Accordingly, TXL protects reperfused diabetic heart through attenu-
ating VE-cadherin-mediated paracellular hyperpermeability via PPAR-a pathway.
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Objectives: Coronary angiography (CAG) and percutaneous coronary intervention
(PCI) are widely used for coronary heart disease (CHD). However, these operations
are performed in the cardiac catheterization laboratory with X-rays. Although the
doctors can wear the heavy protective lead clothes to prevent X-ray radiation, they still
cannot avoid completely the harmful radiation. What’s more, some CAGs and PCIs
are difﬁcult because there are individual differences of coronary structure, which
needs to be operated ﬁnely. The possible robot-assistant manipulation will be great
useful in clinical practice. The study explored the feasibility and the validity of the
new robot operating system for CAG.
Methods: Pigs were anesthetized and 6F sheath was inserted into the femoral artery.
The 5F JR or JL catheter guide-wire was put manually into the sheath and the other
end was connected artiﬁcially with the robot arm. The robot system was controlled
outside of cardiac catheterization laboratory and the robot hand pushed the catheter
into aortic sinus. The catheter was adjusted carefully to forth-back and rotation by
manipulating the robot operating system. After the catheter was engaged well into the
coronary ostium, the robot hand injected the contrast into the coronary.
Results: The new robot operating system had a good control function for CAG. The
rotation angle can be ﬁne-tuned to 0.1 degrees, and the forth-back length can be ﬁne-
tuned to 0.1 mm. The ﬂow and the dose of contrast can be controlled accurately by
using the robot injection system. By manipulating robot system outside of cardiac
catheterization laboratory, we successfully completed the CAGs for 6 pigs without
exposure to X-rays. The operation duration from putting the catheter manually into the
sheath to ﬁnishing CAG was 8.21.2 min. All 6 pigs were survived after CAG.
Conclusions: The new robot operating system has the function of coronary catheter
transmission and rotation. Doctors can avoid or reduce the X-ray radiation exposure
during CAG by using this system. The robot operating system hopefully may become
a clinical advanced medical device for CAG and even PCI.er 16–19, 2014 j GW-ICC Abstracts/Basic and Translational Medicine
